Author

M. M. L. Knott

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7 Pathology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 9 Assay:bulk RNA-seq· 8 Approach:statistical model· 8 Research Focus:differential expression· 6 Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Research Focus:cell type annotation· 3 Research Focus:gene regulatory network inference· 2

Frequent Co-Authors

J. Li· 9 shared S. Ohmura· 9 shared F. Cidre-Aranaz· 8 shared J. Musa· 8 shared M. F. Orth· 8 shared T. L. B. Hoelting· 8 shared A. Marchetto· 7 shared L. Romero-Perez· 7 shared

Activity by Year

2017-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

9 shared papersCancer Biology

J. Li

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Chromosome 8 gain drives cancer progression by hijacking the translation factor 4E-BP1 sensitizing for targeted CDK4/6 inhibition

C. M. Funk, A. Ehlers, M. F. Orth, K. Aljakouch, J. Li, T. L. B. Hoelting, R. Will, A. K. Ceranski, F. Willis, E. Vinca, S. Ohmura, R. Imle, J. Siebenlist, A. Yershova, M. M. L. Knott, , J. Musa

This study identifies chr8 gains and 4E-BP1 expression as prognostic markers in Ewing sarcoma, showing they drive cancer progression by promoting proliferation and sensitizing to CDK4/6 inhibitors.

bioRxiv · Dec 11, 2022 · PreprintCancer Biology

Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma

T. L. B. Hoelting, F. Cidre-Aranaz, D. Matzek, B. Popper, S. J. Jacobi, J. Li, I. Piseddu, B. L. Cadilha, S. Ledderose, J. Zwilling, S. Ohmura, D. Anz, A. Kuenkele, F. Klauschen, T. G. P. Gruenewald, M. M. L. Knott

This paper develops a gene expression strategy that exploits neomorphic DNA-binding of fusion transcription factors in pediatric sarcomas to deliver therapeutic payloads with tumor-specific efficacy.

bioRxiv · Jan 5, 2022Cancer Biology

Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

S. Ohmura, A. Marchetto, M. F. Orth, J. Li, S. Jabar, A. Ranft, E. Vinca, K. Ceranski, M. J. Carreno-Gonzalez, L. Romero-Perez, F. S. Wehweck, J. Musa, F. Bestvater, M. M. L. Knott, T. L. B. Hoelting, , T. G. P. Grunewald

This study identifies RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma, showing its overexpression correlates with poor survival and that its inhibition reduces tumor growth and overcomes chemoresistance.

bioRxiv · Mar 4, 2021Cancer Biology

Systems biology analysis identifies TCF7L1 as a key regulator of metastasis in Ewing sarcoma

F. Cidre-Aranaz, J. Li, T. L. B. Hoelting, M. F. Orth, R. Imle, S. Kutschmann, G. Ammirati, K. Ceranski, M. J. Carreno-Gonzalez, M. Kasan, A. Marchetto, C. M. Funk, F. Bestvater, S. Bersini, C. Arrigoni, , T. G. P. Gruenewald

bioRxiv · Feb 25, 2021 · PreprintCancer Biology

Oncogenic hijacking of a developmental transcription factor evokes therapeutic vulnerability for ROS-induction in Ewing sarcoma

A. Marchetto, S. Ohmura, M. F. Orth, J. Li, F. S. Wehweck, M. M. L. Knott, S. Stein, D. Saucier, C. Arrigoni, J. S. Gerke, M. C. Baldauf, J. Musa, M. Dallmayer, T. L. B. Hoelting, M. Moretti, , T. G. P. Grunewald

The paper identifies SOX6 as a therapeutic target in Ewing sarcoma by showing its role in elevating ROS levels, making the disease vulnerable to ROS-inducing drugs.

bioRxiv · Mar 14, 2019Cancer Biology

Biomarker-based outcome prediction in prostate adenocarcinoma depends on the TMPRSS2-ERG status

J. S. Gerke, M. F. Orth, Y. Tolkach, L. Romero-Perez, F. S. Wehweck, S. Stein, J. Musa, M. M. L. Knott, T. L. B. Hoelting, J. Li, G. Sannino, A. Marchetto, S. Ohmura, F. Cidre-Aranaz, M. Mueller-Nurasyid, , T. G. P. Grunewald

This study identifies subtype-specific prognostic biomarkers in prostate adenocarcinoma, showing that their prognostic value depends on TMPRSS2-ERG fusion status.

bioRxiv · Feb 10, 2019Cancer Biology

SOX2 expression identifies Ewing sarcoma patients with high risk for tumor relapse and poor survival

G. Sannino, A. Marchetto, A. Ranft, S. Jabar, C. Zacherl, R. Alba-Rubio, S. Stein, F. S. Wehweck, M. M. Kiran, T. L. B. Hoelting, J. Musa, L. Romero-Perez, F. Cidre-Aranaz, M. M. L. Knott, J. Li, , T. G. P. Grunewald

bioRxiv · Dec 17, 2018Pathology

Targeting the CALCB/RAMP1-axis inhibits growth of Ewing sarcoma

M. Dallmayer, J. Li, S. Ohmura, R. Alba-Rubio, M. C. Baldauf, T. L. B. Hoelting, J. Musa, M. M. L. Knott, S. Stein, F. Cidre-Aranaz, F. S. Wehweck, L. Romero-Perez, J. S. Gerke, M. F. Orth, A. Marchetto, , T. G. P. Grunewald

This study identifies CALCB as a direct EWSR1-FLI1 target in Ewing sarcoma and shows that targeting the CALCB/RAMP1-axis inhibits tumor growth.

bioRxiv · Dec 8, 2018Cancer Biology

Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets

M. C. Baldauf, M. F. Orth, M. Dallmayer, A. Marchetto, J. S. Gerke, R. Alba Rubio, M. M. Kiran, J. Musa, M. M. L. Knott, S. Ohmura, J. Li, N. Akpolat, A. N. Akatli, O. Ozen, U. Dirksen, , T. G. P. Grunewald

This study identifies ATP1A1, BCL11B, and GLG1 as specific immunohistochemical markers for Ewing sarcoma, offering high specificity for diagnosis.

bioRxiv · Jul 2, 2017Pathology